Beginning of a New Era: Current Progress in Colorectal Cancer Detection, Treatment, and Prognosis
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 20 June 2024 | Viewed by 1359
Special Issue Editors
Interests: medical oncology
2. Department of Oncology, Dell Medical School, University of Texas at Austin, Austin, TX, USA
3. LiveStrong Cancer Institutes, Dell Medical School, University of Texas at Austin, Austin, TX, USA
Interests: pharmacology education; cancer research
Special Issue Information
Dear Colleagues,
Colorectal cancer is one of the most common cancers worldwide, affecting both men and women. Although great advances have been accomplished in the field, with improvement in screening programs, early detection and therapeutic approaches, the mortality remains high. Colorectal cancer is an extremely heterogeneous disease, affecting a diverse patient population. Although the armamentarium of novel treatment modalities and detection tools has grown, providing important improvements in patients selection and outcomes, these new approaches have increased the complexity of treatment algorithms. We now have several different treatment options to offer patients, yet numerous limitations remain. For example, there has been limited progress in the development and clinical use of immunotherapies. Furthermore, there has a pronounced increase in the incidence of early onset colorectal cancer, a disease with many unaddressed needs. Numerous innovations have also emerged in the management of rectal cancer. However, as with colonic cancer, the treatment is complex and defining the most appropriate management is challenging.
In this Special Issue, we will invite experts to support a critical review of the current advancement in the field of colorectal cancer, focusing on recent cutting-edge research and treatment options that may lead to the development of more effective treatments that enhance the survival of patients.
Dr. Anna Capasso
Guest Editor
Dr. Michael William Lee
Co-Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- colon cancer
- rectal cancer
- early onset
- treatment
- immunotherapy
- neoadjuvant
- metastatic
- preclinical research
- translational research
